Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Chemed (CHE)

Chemed Q1 revenue rises 9.8% to $646.9 million; GAAP EPS up 14.6% to $4.86

Positive Impact 3 of 5 earnings Written later

Chemed Corporation reported first-quarter 2025 results for the period ended March 31, 2025, with revenue up 9.8% to $646.9 million and GAAP diluted EPS up 14.6% to $4.86. VITAS revenue and profit grew, while Roto-Rooter adjusted EBITDA fell 2.4%, and the company said it will provide updated 2025 earnings guidance with its June 30, 2025 release.

Key points

  • Revenue increased 9.8% to $646.9 million; GAAP diluted EPS was $4.86, up 14.6%.
  • Adjusted diluted EPS was $5.63, up 8.3%.
  • VITAS net patient revenue rose 15.1% to $407.4 million; Roto-Rooter revenue rose 1.8% to $239.5 million.
  • Roto-Rooter adjusted EBITDA fell 2.4% to $59.2 million; the company will update 2025 guidance on June 30, 2025.

The filing

CompanyChemed (CHE)
Form8-K, current report
Filed with the SECApr 23, 2025, 4:30 PM ET
Accession number0001562762-25-000088

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 23, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.